Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-Negative Metastatic Breast Cancer|Recurrent Ovarian Cancer
Interventions: DRUG: Durvalumab|DRUG: Eribulin
Sponsor: Amy Tiersten
Collaborators: AstraZeneca|Eisai Inc.